RadNet (RDNT) Acquires Gleamer for €230 Million

RadNet, Inc. (NASDAQ:RDNT) is one of the 10 Best Diagnostics and Research Stocks to Buy According to Analysts.

RadNet (RDNT) Acquires Gleamer for €230 Million

On March 2, 2026, RadNet, Inc. (NASDAQ:RDNT) announced the acquisition of Paris-based Gleamer SAS for up to €230 million. The acquisition positions the company’s subsidiary, DeepHealth, as the world’s largest radiology AI provider. Gleamer services 700 global contracts. It reported a 90% ARR growth rate between 2022 and 2025 and is expected to reach $30 million in ARR by 2026. Structured as an all-cash transaction, Gleamer’s takeover integrates FDA-cleared X-ray and musculoskeletal AI into DeepHealth’s portfolio, covering all major imaging modalities. RadNet, Inc. (NASDAQ:RDNT) anticipates significant cost effectiveness and diagnostic automation capabilities from the integration in the third quarter of 2026.

Following the acquisition, RadNet, Inc. (NASDAQ:RDNT)’s DeepHealth unveiled the industry’s most comprehensive native clinical AI portfolio at ECR 2026 on March 4, 2026. The platform integrates Gleamer’s AI solutions for MR, CT, X-ray, Ultrasound, and Mammography to establish clinical AI suites covering breast, chest, neuro, and prostate care. With these modular suites, DeepHealth aims to stage-shift disease through earlier detection and automated reporting.

Founded in 1981, RadNet, Inc. (NASDAQ:RDNT) is the largest U.S. operator of outpatient diagnostic imaging centers. Its headquarters is in California.

READ NEXT: 10 Best Stocks to Invest in During a Recession and 10 Best Space Exploration Stocks to Buy According to Analysts

Disclosure: None.  Follow Insider Monkey on Google News.